Anteris Technologies hails FDA early feasibility study approval for DurAVR™

News Direct

Dec 06, 2022

–News Direct–

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

View original content to download multimedia: https://newsdirect.com/news/anteris-technologies-hails-fda-early-feasibility-study-approval-for-duravr-684411792

YOU MAY ALSO LIKE

Reform of Africa’s Criminal Justice Systems

--News Direct--Contact DetailsProactive InvestorsJonathan Jackson+61 413 713 744Jonathan@proactiveinvestors.comView original content to download multimedia: https://newsdirect.com/news/anteris-technologies-hails-fda-early-feasibility-study-approval-for-duravr-684411792

read more

Bluepeak Reaches Major Milestone of 100,000 Customers

--News Direct--Contact DetailsProactive InvestorsJonathan Jackson+61 413 713 744Jonathan@proactiveinvestors.comView original content to download multimedia: https://newsdirect.com/news/anteris-technologies-hails-fda-early-feasibility-study-approval-for-duravr-684411792

read more

Green Global FX Introduces AI-Powered Signals App…

--News Direct--Contact DetailsProactive InvestorsJonathan Jackson+61 413 713 744Jonathan@proactiveinvestors.comView original content to download multimedia: https://newsdirect.com/news/anteris-technologies-hails-fda-early-feasibility-study-approval-for-duravr-684411792

read more